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acids in pregnant women dates back to 1985, when Olsen SF published
the results of the first conducted observational study of the effect of di-
etary fish oil on the outcome of pregnancy [1]. Although further studies
did not independently examine the role of docosahexaenoic acid (DHA)
versus eicosapentaenoic acid (EPA), today we know that DHA seems to
be responsible for the majority of the observed effects. It is also well
established that LC-PUFAs, particularly DHA, are critical to fetal growth,
neural and retinal development.
After 23 years, again Olsen SF and co-authors, present interesting
data based on analysis performed on a large group of 91,661 preg-
nant women [2]. This is the first study to examine whether deter-
mined values of plasma EPA-DHA concentration, evaluated on 9th
and 25th week of pregnancy are associated with the risk of subse-
quent early preterm birth. Authors showed a threshold effect of
plasma EPA-DHA concentrations between 2.0% and 2.5% with a sig-
nificantly increased risk of early preterm birth below these values,
which then flattened sharply out at higher plasma EPA-DHA levels.
These results allow us to conclude that evaluation of plasma EPA-
DHA concentration in the first trimester of pregnancy and continuing
in the second and maybe the third trimester, might become a stan-
dard form of monitoring, which could suggest interventions like die-
tary intake or supplementation of EPA-DHA.
It is widely accepted that one of the reasons for early preterm births
is uteroplacental ischemia resulting from disturbances during the pro-
cess of placentation. Recently Carvajal JA [3] suggested that DHA supple-
mentation early in pregnancy might prevent placental ischemia and
deep placentation disorders (preeclampsia, fetal growth restriction).
Whether plasma EPA-DHA concentrations between 2.0% and 2.5% are
optimal for prevention of placentation disordersmay be explained in fu-
ture clinical observations.
It is also known that DHA and other fatty acids are associatedwith
fetal insulin sensitivity and beta-cell function. Recently Zhao JP and
co-authors [4], found that low circulating DHA levels may cause
compromised fetal insulin sensitivity, that may be involved in peri-
natally programming the susceptibility to type 2 diabetes in theDOI of original article: https://doi.org/10.1016/j.ebiom.2018.07.009.
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trations in diabetic mothers might be determined in future
investigations.
Mother's-body EPA – DHA stores represent the only source of these
fatty acids for the fetus. Both EPA and DHA are actively transported
across the placenta to the growing intrauterine child. It seems to be es-
pecially important during the third trimester of pregnancy, when the
weight of fetal brain weight increases from 75 g to 400 g (between
23rd-40th weeks of pregnancy). The rate of DHA accretion into the
brain during the last 17 weeks of pregnancy is comparable to that
which occurswithin the next 80weeks of life. On the other hand, the ac-
cretion of EPA into the brain is negligible. Moreover, it was also found
that higher DHA levels in the first few days of life are associated with
a decreased number of intraventricular haemorrhages and improved
outcomes in preterm born children [5].
The range of doses for EPA-DHA supplementation that are generally
recommended for pregnantwomen is relatively wide, from 200mg/day
to 1000 mg/day. The results presented by Olsen and co-authors, clearly
underline the importance of obtaining target plasma EPA-DHA concen-
trations regardless of the amount of fatty acids dose. It means that the
obstetrician should not recommend one constant dose of supplement,
but rather ought to adjust the dosage according to the results of plasma
EPA-DHA concentration evaluation. It is especially true because the
transfer of fatty acids from the mother to the developing fetus during
normal pregnancy decreases maternal plasma DHA levels [6, 7].
Nevertheless, the results obtained from this study do not explain the
proportions of plasma EPA/DHA concentrations that were preventing
preterm delivery. One may speculate, that proportions are not stable
throughout pregnancy and depend on the transport activity from
mother to fetus. As we know, the accretion of DHA into the brain of de-
veloping fetus during the last trimester of pregnancy is significant and
may influence the proportions of EPA/DHA markedly.
In my opinion, the most important conclusion that comes out from
this study is the need for plasma EPA-DHA concentration monitoring
during pregnancy. The proportions of EPA/DHA in supplementation
should be established in future investigations.
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